Table 2.

Induction therapies and monoclonal antibodies time-related variables.

DMT	Treatment duration, median [range] (years)	Time since last infusion, median [range] (months)
Cladribine	0.51 [0.21-1.8]	3.97 [1.47-7.87]
Alemtuzumab	4.27 [0.58-5.74]	33.53 [6.97-55.9]
Natalizumab	0.18 [0.16-0.21]
Ocrelizumab	1.46 [0.41-4.22]	3.73 [2.26-4.63]
Rituximab	1.76 [0.42-4.15]	6.07 [4.73-6.83]

DMT, disease modifying therapy.